# Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)

Source: https://onco.cc/trials/nct05717803/  
OnCo record `nct05717803` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in lung cancer, run by Fudan University, now recruiting.

## Summary

Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012) is a phase 3, interventional study registered as NCT05717803 by Fudan University, with a registry enrolment figure of 307 participants, started 2023-02-15 and due to reach its primary completion in 2028-12-31. Interventions recorded: Segmentectomy. Conditions listed: Segmentectomy; Lung Adenocarcinoma. Primary outcome: 5-year disease-free survival. Lung eligibility wording from the registry: "* Not receiving lung cancer surgery before;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05717803
- Phase: 3
- Setting: Segmentectomy for Ground Glass-dominant Invasive Lung Cancer With Size of 2-3cm: a Single-arm, Multi-center, Phase III Trial
- Sponsor: Fudan University
- Enrolled: 307

## Sources

- ClinicalTrials.gov NCT05717803: https://clinicaltrials.gov/study/NCT05717803

## Connected records

- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05717803.json